Objectives In the HIV-1-positive population, a paradigm shift from three-drug regimens
(3DRs) to dolutegravir-based two-drug regimens (2DRs) both as initial and switch treatment …

Background The integrase strand transfer inhibitor dolutegravir (DTG) is being introduced
into low-and middle-income countries (LMICs) as an alternative to first-line treatment with …

A key goal of managing HIV in pregnancy and postpartum is to optimise a woman's own
health. Furthermore, one of the major successes in the management of individuals living …

Background Although antiretroviral regimens containing integrase inhibitors rapidly
suppress HIV viral load in non-pregnant adults, few published data from randomised …

2 METHODS The Spectrum PMTCT “stacked bar” analysis (Figure 1) uses programmatic
and modelled data to estimate new child HIV infections and attributes those infections to one …

Background: Integrase strand transfer inhibitors (InSTIs) decrease HIV plasma viral load
faster than other antiretroviral classes. More rapid viral load decline has been associated …

Background In sub-Saharan Africa, individuals infected with HIV who are severely
immunocompromised have high mortality (about 10%) shortly after starting antiretroviral …

The integrase inhibitors elvitegravir (EVG) and dolutegravir (DTG) rapidly decrease the
plasma HIV-1 viral load, a key factor in the prevention of maternal-to-fetal transmission of …

Background Predicting drug pharmacokinetics in pregnant women including placental drug
transfer remains challenging. This study aimed to develop and evaluate maternal–fetal …

Objectives: Given the success of combination antiretroviral therapy (cART) in treating HIV
viremia, drug toxicity remains an area of interest in HIV research. Despite newer integrase …